{
    "clinical_study": {
        "@rank": "72268", 
        "arm_group": [
            {
                "arm_group_label": "Formulation 1 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval"
            }, 
            {
                "arm_group_label": "Formulation 2 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval"
            }, 
            {
                "arm_group_label": "Formulation 3 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval"
            }, 
            {
                "arm_group_label": "Formulation 4 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval"
            }, 
            {
                "arm_group_label": "Formulation 5 Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this group will receive two doses of placebo at a 21 day interval"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and immunogenicity of different\n      formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age."
        }, 
        "brief_title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults who are 18 to 64 years of age (inclusive) at the time of first\n             study vaccination.\n\n          -  Written informed consent obtained from subject.\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol .\n\n          -  Healthy subjects as established by medical history and physical examination.\n\n          -  Access to a consistent means of telephone contact.\n\n          -  For subjects who undergo a screening visit: results of all safety laboratory tests\n             obtained at the screening visit must be within reference ranges. Results of any\n             repeat testing cannot be used to qualify a subject for enrolment.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n             Non-childbearing potential is defined as current tubal ligation, hysterectomy,\n             ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if they\n\n               -  have practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  have a negative pregnancy test on the day of vaccination, and\n\n               -  agree to continue to practice adequate contraception until 2 months after the\n                  last dose administered.\n\n        Exclusion Criteria:\n\n          -  Presence or evidence of neurological or psychiatric diagnoses which, although stable,\n             are deemed by the investigator to render the potential subject unable/unlikely to\n             provide accurate safety reports.\n\n          -  Presence or evidence of substance abuse.\n\n          -  Diagnosed with cancer, or treatment for cancer within three years.\n\n          -  Diagnosed with excessive daytime sleepiness, or narcolepsy; or history of narcolepsy\n             in a subject's parent, sibling or child.\n\n          -  Presence of a temperature \u2265 38.0\u00baC (\u2265100.4\u00baF), or acute symptoms greater than \"mild\"\n             severity on the scheduled date of first vaccination.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including\n             history of human immunodeficiency virus (HIV) infection.\n\n          -  Receipt of systemic glucocorticoids within 30 days prior to the first dose of study\n             vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs\n             within 6 months of first study vaccine/ placebo dose.\n\n          -  Any significant disorder of coagulation or treatment with warfarin derivatives or\n             heparin.\n\n          -  An acute evolving neurological disorder or Guillain Barr\u00e9 Syndrome within 42 days of\n             receipt of prior seasonal or pandemic influenza vaccine.\n\n          -  Administration of an inactive vaccine within 14 days or of a live attenuated vaccine\n             within 30 days before the first dose of study vaccine/placebo.\n\n          -  Planned administration of any vaccine other than the study vaccine/placebo before\n             blood sampling at the Day 42 visit.\n\n          -  Previous administration of any H7 vaccine or physician-confirmed H7 disease.\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine/placebo, or planned use\n             during the study period.\n\n          -  Receipt of any immunoglobulins and/or any blood products within 90 days before the\n             first dose of study vaccine/placebo, or planned administration of any of these\n             products during the study period.\n\n          -  Any known or suspected allergy to any constituent of influenza vaccines or component\n             used in the manufacturing process of the study vaccine including a history of\n             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse\n             reaction to a previous influenza vaccine.\n\n          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin (\u03b2-hCG) test\n             result before the first dose of study vaccine/placebo.\n\n          -  Lactating or nursing women.\n\n          -  Any condition which, in the opinion of the investigator, prevents the subject from\n             participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "424", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999842", 
            "org_study_id": "201072"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Formulation 1 Group", 
                    "Formulation 3 Group", 
                    "Formulation 2 Group", 
                    "Formulation 4 Group"
                ], 
                "description": "One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21", 
                "intervention_name": "Investigational H7N9 vaccine GSK3206641A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Formulation 5 Group", 
                "description": "One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21", 
                "intervention_name": "Investigational H7N9 vaccine GSK3206640A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "H7N9", 
            "Influenza", 
            "Safety", 
            "Adults", 
            "Adjuvant", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32216"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30281"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boise", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83642"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erie", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16506"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Truro", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B2N 1L2"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodstock", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N4S 5P5"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 2G2"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The following aggregate variables will be calculated for each adjuvanted H7N9 vaccine group: \u2022 Seroconversion rates (SCR); \u2022 Seroprotection rates (SPR); \u2022 Mean Geometric Increase (MGI)", 
                "measure": "Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "At Day 42"
            }, 
            {
                "measure": "Occurrence of each solicited local symptom", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination"
            }, 
            {
                "measure": "Occurrence of each solicited general symptom", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination"
            }, 
            {
                "measure": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "safety_issue": "No", 
                "time_frame": "At Day 0 visit"
            }, 
            {
                "measure": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "safety_issue": "No", 
                "time_frame": "At Day 7 visit"
            }, 
            {
                "measure": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "safety_issue": "No", 
                "time_frame": "At Day 21 visit"
            }, 
            {
                "measure": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "safety_issue": "No", 
                "time_frame": "At Day 28 visit"
            }, 
            {
                "measure": "Occurrence of clinical safety laboratory abnormalities reported for samples", 
                "safety_issue": "No", 
                "time_frame": "At Day 42 visit"
            }, 
            {
                "measure": "Occurrence of unsolicited adverse events", 
                "safety_issue": "No", 
                "time_frame": "21 days after each dose"
            }, 
            {
                "measure": "Occurrence of Medically Attended Adverse Events (MAEs), potential Immune Mediated Diseases (pIMDs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 until the Day 42"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following aggregate variables will be calculated for each adjuvanted (GSK3206641A) vaccine group which successfully meets CBER and CHMP criteria, and for the unadjuvanted (GSK3206640A) plain antigen vaccine group: \u2022 Geometric mean reciprocal serum HI antibody titers (GMTs); \u2022 SCR", 
                "measure": "Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "At Day 42"
            }, 
            {
                "description": "The following aggregate variables will be calculated for the unadjuvanted plain antigen vaccine group: \u2022 SCR; \u2022 SPR; \u2022 MGI", 
                "measure": "Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "At Day 42"
            }, 
            {
                "description": "The following aggregate variables will be calculated for each study group: \u2022 GMTs; \u2022 Seropositivity rates; \u2022 SCR; \u2022 SPR; \u2022 MGI", 
                "measure": "Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers", 
                "safety_issue": "No", 
                "time_frame": "GMTs and Seropositivity rates at Days 0, 21, 42 and Months 6 and 12; SCR and MGI at Day 21, 42 (Placebo group only) and Months 6 and 12; SPR at Days 0, 21, 42 (Placebo group only) and Months 6 and 12"
            }, 
            {
                "description": "The following aggregate variables will be calculated for each study group by age stratum (18-40 years; 41-64 years): \u2022 GMTs; \u2022 Seropositivity rates; \u2022 SCR; \u2022 SPR; \u2022 MGI", 
                "measure": "Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers by age stratum", 
                "safety_issue": "No", 
                "time_frame": "GMTs, Seropositivity rates and SPR at Days 0, 21, 42 and Months 6 and 12;  SCR and MGI at Day 21, 42 and Months 6 and 12"
            }, 
            {
                "description": "The following parameters will be calculated for a subset of subjects in each study group: \u2022 GMTs; \u2022 Seropositivity rates; \u2022 Vaccine response rate (VRR)", 
                "measure": "Humoral immune response in terms of vaccine homologous (H7N9) neutralizing (MN) antibody titers", 
                "safety_issue": "No", 
                "time_frame": "GMTs and Seropositivity rates at Days 0, 21, 42 and Month 6;  VRR at Days 21, 42 and Month 6"
            }, 
            {
                "measure": "Occurrence of MAEs, pIMDs and SAEs", 
                "safety_issue": "No", 
                "time_frame": "Until the Month 12 visit"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}